GlaxoSmithKline headquarters in London on Jan. 17, 2022.
Hannah Mckay | Reuters
Britain’s second-largest drugmaker GSK has entered an settlement to amass U.S.-based drugmaker Nuvalent for $10.6 billion to bolster its oncology pipeline, in what can be its largest acquisition in additional than a decade.
The all-cash deal values Nuvalent at about $124 per share, in keeping with a GSK submitting on Tuesday, representing a 40% premium to its final closing worth. Nuvalent shares have been final seen buying and selling 39% increased in U.S. premarket buying and selling. GSK shares fell 2.6% in London.
The Monetary Occasions had reported the transaction earlier on Tuesday. Nuvalent didn’t reply to a request for remark.
Nuvalent is a specialist oncology, late-stage growth biotech firm centered on subsets of lung most cancers with particular genetic mutations. The acquisition is anticipated to assist GSK offset a drop in income anticipated when its best-selling HIV drugs loses exclusivity from 2028.
The deal would give GSK entry to Nuvalent’s two late-stage lung most cancers therapies, which GSK stated have blockbuster potential. The acquisition additionally contains an early-stage drugs in addition to Nuvalent’s preclinical portfolio of a number of packages.
“The acquisition gives GSK with rapid new gross sales development alternatives,” GSK CEO Luke Miels stated in an announcement. “The 2 lead merchandise are potential best-in-class belongings that would launch this yr if authorised by the FDA and provide important new therapy choices to sufferers with two types of non-small cell lung most cancers.”
Barclays analysts stated the deal is smart conceptually because it provides clinically de-risked late-stage belongings to GSK’s current oncology enterprise. They, nonetheless, questioned the mega blockbuster standing of the 2 late-stage belongings – zidesamtinib and neladalkib – saying that the upside was “capped.”
“The acquisition … would speed up GSK entry into the lung most cancers house,” Barclays stated. “Extra importantly, the deal accretion may assist offset HIV [loss of exclusivity] headwind beginning in mid-28.
There isn’t a change to GSK’s 2026 full-year steerage of core working revenue and core earnings-per-share development, the corporate stated, anticipating the acquisition to contribute to income development from 2027.
GSK Plc
The deal is the second largest acquisition in GSK’s historical past, trailing its 2014 asset swap with Novartis during which it assumed management of the Swiss drugmaker’s vaccines division in a transaction valued at $20 billion.
It will additionally mark a notable departure from the corporate’s deal with smaller transactions in recent times.
Miels, who took over the job from longtime boss Emma Walmsley in the beginning of the yr, advised buyers in February that he would deal with transactions within the £2 billion ($2.67 billion) to £4 billion vary that have been “hiding in plain sight.”
Miels has been tasked with overhauling an organization that has struggled to allay investor considerations about its drug pipeline. GSK’s share worth has climbed roughly 29% since Miels’ appointment was introduced in September.
Nuvalent’s lead asset, neladalkib — a remedy that targets sure kinds of lung most cancers — is at present present process FDA evaluate with a deadline of Nov. 27.
The corporate additionally has a brand new drug software for zidesamtinib, for sufferers with a sort of most cancers often known as ROS1-positive non-small cell lung most cancers, below FDA evaluate.
Analysts at CGS Worldwide estimated that if authorised, neladalkib and zidesamtinib may generate mixed annual revenues of $823 million within the 2029 monetary yr, in a January notice to buyers.
The deal additionally comes at a time of biotech dealmaking frenzy, pushed by looming patent cliffs, newly buoyant public markets and pharma giants’ race to bolster their pipelines. Biotech offers globally reached $106 billion throughout 201 transactions to date in 2026, in keeping with PitchBook information, placing the sector on observe for its strongest yr because the pre-pandemic peak.
